Skip to main content

Table 1 Characteristics of the studies included in the systematic review on vascular resection in patients with retroperitoneal sarcoma

From: Aggressive surgical approach with vascular resection and reconstruction for retroperitoneal sarcomas: a systematic review

Study

Patients

Histological subtype (%)

FNCLCC grade (%)

Tumour status (%)

Follow-up (months)

Vascular resection (%)

Margin status (%)

30-day mortality (%)

Complication rate (%)

RFS (%)

OS (%)

Dzsinich 199216

13

Lei, 100

NA

P, 100

27

IVC 100

R0/R1 93

7

23

31

3y 38

Mingoli A199717

120

Lei, 100

NA

P, 100

32

IVC 100

R0/R1 100

3

6

42

5y 37

Hines199918

14

Lei, 100

G1, 14; G2, 29; G3, 51

P, 100

25

IVC 100

R0/R1 86; R2 14

0

NA

43

5y 53

Hollenbeck 200319

21

Lei, 100

NA

P, 100

24

IVC 100

R0/R1 84; R2 16

10

19

33

5y 33

Kieffer 200620

20

Lei, 100

NA

P, 100

44

IVC 100

NA

20

NA

15

5y 35

Schwarzbach 200621

25

Lip, 16; Lei, 48; MFH, 8

G1, 8; G2, 20; G3, 68

P, 64; R, 36

19

IVC 48

IV 16

AA 24

IA 12

R0/R1 68; R2 32

4

36

18

2y 56

Ito 200722

20

Lei, 100

G1, 10; G2, 35; G3, 50

P, 100

47

IVC 100

R0/R1 95; R2 5

0

NA

30

5y 62

Fiore 201223

15

Lip, 7; Lei, 80

G1, 20; G2, 27; G3, 53

P, 100

32

IVC 100

R0/R1 100

0

7

67

3y 80

Mann 201224

17

Lei, 100

G1, 6; G2, 47; G3, 47

P, 82; R, 18

49

IVC 100

R0/R1 100

0

35

41

5y 56

Bertrand 201625

22

Lip, 54; Lei, 32

G1, 6; G2, 42; G3, 42

P, 65; R, 35

34

IVC 59

IV 41

IA 36

AA 9

R0/R1 100

0

18

NA

3y 61

Cananzi 201626

11

Lei, 100

G1, 27; G2, 27; G3, 36

P, 100

93

IVC 100

R0/R1 91; R2 9

0

9

36

5y 78

Illuminati 201627

27

Lei, 100

NA

P, 100

60

IVC 67

IV 33

R0/R1 100

0

22

33

5y 54

Roland 201628

42

Lei, 100

G1, 11; G2, 26; G3, 63

P, 100

60

IVC 100

R0/R1 80; R2 20

0

NA

35

5y 65

Tan 201629

67

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

Wortmann 201630

20

NA

NA

P, 64; R, 36

24

IV 10

IA 70

AA 25

NA

5

35

33

2y 69

Ikoma 201731

36

Lei, 100

NA

NA

NA

IVC 100

R0/R1 100

NA

NA

NA

NA

Blair 201832

32

Lip, 19; Lei, 81

G1, 44; G2, 47; G3, 9

P, 84; R, 16

37

IVC 100

R0/R1 91; R2 9

0

16

25

5y 50

Ferraris 201933

67

Lip, 25; Lei, 58

G1, 10; G2, 43; G3, 46

P, 93; R, 7

58

IVC 64

IV 42

AA 6

IA 19

R0/R1 97; R2 3

3

22

40

5y 56

Homsy 202034

17

Lip, 29; Lei, 59

G1, 0; G2, 35; G3, 59

P, 94; R, 6

27

IVC 53

IV 24

AA 35

IA 18

R0/R1 68; R2 32

0

29

47

3y 80

Ong 202035

30

Lei, 100

G1, 13; G2, 63; G3, 23

P, 100

70

IVC 67

IV 33

IA 20

R0/R1 97; R2 3

0

17

43

5y 32

Spolverato 202110

24

Lip, 100

G1, 25; G2, 54; G3, 21

P, 100

38

IVC 38

IV 50

IA 29

R0/R1 96; R2 4

0

54

52

5y 60

Goel 202236

24

Lei, 100

NA

P, 100

25

IVC 100

R0/R1 100

4

4

38

5y 25

Li 202237

15

Lip, 53; Lei, 13

NA

P, 60; R, 40

21

IVC 20

IA 100

R0/R1 100

0

13

86

5y 73

  1. Lip, Liposarcoma; Lei, Leiomyosarcoma; MFH, Malignant fibrous histiocytoma; P, Primary; R, Recurrent; NA, data not available; R status, Resection status; IVC, Inferior vena cava; IV, Iliac vein; IA, Iliac artery; AA, Abdominal aorta